A Phase 3 interventional study of GWP42003-P and Placebo in Tuberous Sclerosis Complex and Seizures, sponsored by Jazz Pharmaceuticals. Completed at 44 sites in 6 countries. Open to participants aged 1 Year to 65 Years. Per ClinicalTrials.gov, last updated 2022-09-28.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Tuberous Sclerosis with a site in United States — 8 open to participants now, 15 under way, 1 of them phase 3. Tuberous Sclerosis · United States.
Among the 63 studies in Tuberous Sclerosis with a site in United States, this one is the 2nd largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2016, is one of 10 in phase 3, and was the 30th registered.
115 studies on the registry are indexed under Tuberous Sclerosis; 27 are open to participants now.
Browse Tuberous Sclerosis studies →8 of the 63 studies in Tuberous Sclerosis with a site in United States are open now. Recruiting first, the newest first:
David M. Ritter · Sites in United States
Women only
St. Jude Children's Research Hospital · Sites in United States
National Tuberous Sclerosis Association · Sites in United States, Canada
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–90
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 2–90 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Tuberous Sclerosis studies recruiting now, 10 (48%) set no upper age limit and 8 (38%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: 1 Year to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 23 · Phase 3 11 · Phase 4 3
First in 1995; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 224 is above the median of 52 across 73 interventional studies indexed under Tuberous Sclerosis.
Median enrollment 52 across the 47 interventional studies, 300 across the 15 observational. Of the 44 that completed or were terminated, 25 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 63 have an industry lead sponsor. The 10 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 6 studies filed under Tuberous Sclerosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Tuberous Sclerosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02962414Phase 3Novartis PharmaceuticalsRoll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | 2027-02-26 |
| NCT06139172Rush University Medical CenterWeb Intervention for Parents of Youth With Genetic Syndromes (WINGS) | 2026-12 |
| NCT06879665Vrije Universiteit BrusselTANDem-2: Closing the Gap to Interventions for TAND | 2026-12-31 |
| NCT05104983Darcy KruegerStopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | 2027-06-30 |
| NCT05044819Jazz PharmaceuticalsAssessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 63 studies in Tuberous Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record. Participants will receive 1 of 2 doses of GWP42003-P or matching placebo. The primary clinical hypothesis is that there will be a difference between GWP42003-P and placebo in their effect on seizure frequency.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
Drug: GWP42003-P
100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
Drug: GWP42003-P
Placebo oral solution matching 100 mg/mL GWP42003-P.
Drug: Placebo
Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Also known as: Cannabidiol, CBD
Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration)
TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that are countable. Percent change from Baseline was calculated as the (post-Baseline value minus the Baseline value) divided by the Baseline value x 100.
Time frame: Baseline; up to Week 16
Number of Participants Considered Treatment Responders During the Treatment Period (Maintenance and Titration)
Treatment responders are defined as those participants with a ≥ 50% reduction in TSC-associated seizure frequency. TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that are countable. Participants who withdrew from the trial during the treatment period are considered non-responders.
Time frame: Baseline; up to Week 16
Change From Baseline in the Caregiver Global Impression of Change (CGIC) or Participant Global Impression of Change (PGIC) Score at the Participant's Last Visit
The combined caregiver and participant summary uses either the caregiver or participant version if only one version was completed, or the caregiver version if both caregiver and participant versions were completed. The CGIC comprised the following question, to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since your child started treatment, please assess the status of your child's overall condition (comparing their condition now to their condition before treatment)." The SGIC comprised the following question, to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since you started treatment, please assess the status of your overall condition (comparing your condition now to your condition before treatment)."
Time frame: Baseline; up to Week 16
Percent Change From Baseline in Total Seizures During the Treatment Period (Maintenance and Titration)
Total seizures included all seizure types combined. Percent change from Baseline was calculated as the (post-Baseline value minus the Baseline value) divided by the Baseline value x 100.
Time frame: Baseline; up to Week 16
Number of Participants With Any Severe Treatment-emergent Adverse Event (TEAE)
A TEAE was defined as an AE with a start date on or after the first dose of IMP during the Blinded Phase up to and including the date of first dose of the Open-label Extension (OLE) Phase (OLE Day 1).
Time frame: up to approximately Week 22
| Milestone | GWP42003-P 25 mg/kg/Day | GWP42003-P 50 mg/kg/Day | Placebo |
|---|---|---|---|
| Started | 75 | 73 | 76 |
| Completed | 65 | 61 | 75 |
| Not completed | 10 | 12 | 1 |
| Withdrew: Adverse event | 8 | 8 | 0 |
| Withdrew: Withdrawn by parent/guardian | 1 | 1 | 1 |
| Withdrew: Met withdrawal criteria | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Difficulties taking imp | 1 | 0 | 0 |
TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that are countable. Percent change from Baseline was calculated as the (post-Baseline value minus the Baseline value) divided by the Baseline value x 100.
| percent change | GWP42003-P 25 mg/kg/Day | GWP42003-P 50 mg/kg/Day | Placebo |
|---|---|---|---|
| Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) | -43.36 (-67.8 to -13.6) | -36.55 (-67.0 to -5.5) | -20.08 (-47.1 to 3.1) |
Treatment responders are defined as those participants with a ≥ 50% reduction in TSC-associated seizure frequency. TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that are countable. Participants who withdrew from the trial during the treatment period are considered non-responders.
| Participants | GWP42003-P 25 mg/kg/Day | GWP42003-P 50 mg/kg/Day | Placebo |
|---|---|---|---|
| Responders | 27 | 29 | 17 |
| Non-responders | 48 | 44 | 59 |
The combined caregiver and participant summary uses either the caregiver or participant version if only one version was completed, or the caregiver version if both caregiver and participant versions were completed. The CGIC comprised the following question, to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since your child started treatment, please assess the status of your child's overall condition (comparing their condition now to their condition before treatment)." The SGIC comprised the following question, to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since you started treatment, please assess the status of your overall condition (comparing your condition now to your condition before treatment)."
| units on a scale | GWP42003-P 25 mg/kg/Day | GWP42003-P 50 mg/kg/Day | Placebo |
|---|---|---|---|
| Caregiver | 3.0 ± 1.34 | 3.1 ± 1.40 | 3.5 ± 0.93 |
| Combined Caregiver and Participant | 3.0 ± 1.35 | 3.2 ± 1.45 | 3.5 ± 0.96 |
| Participant | 3.3 ± 1.51 | 4.5 ± 1.73 | 2.8 ± 1.26 |
Total seizures included all seizure types combined. Percent change from Baseline was calculated as the (post-Baseline value minus the Baseline value) divided by the Baseline value x 100.
| percent change | GWP42003-P 25 mg/kg/Day | GWP42003-P 50 mg/kg/Day | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Total Seizures During the Treatment Period (Maintenance and Titration) | -34.71 ± 46.150 | -35.14 ± 42.530 | -19.63 ± 35.137 |
A TEAE was defined as an AE with a start date on or after the first dose of IMP during the Blinded Phase up to and including the date of first dose of the Open-label Extension (OLE) Phase (OLE Day 1).
| Participants | GWP42003-P 25 mg/kg/Day | GWP42003-P 50 mg/kg/Day | Placebo |
|---|---|---|---|
| Number of Participants With Any Severe Treatment-emergent Adverse Event (TEAE) | 7 | 9 | 1 |
Collected over up to approximately Week 22. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GWP42003-P 25 mg/kg/Day | 0/75 (0%) | 16/75 (21.3%) | 66/75 (88%) |
| GWP42003-P 50 mg/kg/Day | 0/73 (0%) | 10/73 (13.7%) | 71/73 (97.3%) |
| Placebo | 0/76 (0%) | 2/76 (2.6%) | 68/76 (89.5%) |
| Event | GWP42003-P 25 mg/kg/Day | GWP42003-P 50 mg/kg/Day | Placebo |
|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 2/75 | 2/73 | 0/76 |
| Aspartate aminotransferase increasedInvestigations | 2/75 | 2/73 | 0/76 |
| Transaminases increasedInvestigations | 0/75 | 2/73 | 0/76 |
| VomitingGastrointestinal disorders | 2/75 | 0/73 | 0/76 |
| Gastroenteritis viralInfections and infestations | 2/75 | 0/73 | 0/76 |
| Status epilepticusNervous system disorders | 2/75 | 0/73 | 1/76 |
| Abdominal painGastrointestinal disorders | 0/75 | 1/73 | 0/76 |
| DiarrhoeaGastrointestinal disorders | 0/75 | 1/73 | 0/76 |
| GastroenteritisInfections and infestations | 0/75 | 1/73 | 0/76 |
| LacerationInjury, poisoning and procedural complications | 0/75 | 1/73 | 0/76 |
| Event | GWP42003-P 25 mg/kg/Day | GWP42003-P 50 mg/kg/Day | Placebo |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 23/75 | 40/73 | 19/76 |
| SomnolenceNervous system disorders | 10/75 | 19/73 | 7/76 |
| Decreased appetiteMetabolism and nutrition disorders | 15/75 | 17/73 | 9/76 |
| Alanine aminotransferase increasedInvestigations | 7/75 | 14/73 | 0/76 |
| PyrexiaGeneral disorders | 14/75 | 12/73 | 6/76 |
| VomitingGastrointestinal disorders | 12/75 | 13/73 | 7/76 |
| Aspartate aminotransferase increasedInvestigations | 6/75 | 12/73 | 0/76 |
| Gamma-glutamyltransferase increasedInvestigations | 12/75 | 10/73 | 0/76 |
| NasopharyngitisInfections and infestations | 11/75 | 11/73 | 12/76 |
| Upper respiratory tract infectionInfections and infestations | 7/75 | 7/73 | 10/76 |
Baseline data are reported for members of the Safety Analysis Set, comprised of participants randomized to treatment who received at least 1 dose of investigational medicinal product (IMP).
| Age, Continuous(years) | GWP42003-P 25 mg/kg/Day | GWP42003-P 50 mg/kg/Day | Placebo | Total |
|---|---|---|---|---|
| Mean | 14.112 ± 10.8131 | 12.915 ± 8.5324 | 13.918 ± 10.6302 | 13.659 ± 10.0324 |
| Sex: Female, Male(Participants) | GWP42003-P 25 mg/kg/Day | GWP42003-P 50 mg/kg/Day | Placebo | Total |
|---|---|---|---|---|
| Female | 32 | 30 | 31 | 93 |
| Male | 43 | 42 | 44 | 129 |
| Race/Ethnicity, Customized(Participants) | GWP42003-P 25 mg/kg/Day | GWP42003-P 50 mg/kg/Day | Placebo | Total |
|---|---|---|---|---|
| White/Caucasian | 68 | 65 | 66 | 199 |
| Black/African American | 2 | 3 | 0 | 5 |
| American Indian/Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 1 | 0 | 3 | 4 |
| Biracial Causasian-African American | 1 | 0 | 0 | 1 |
| Latin | 1 | 0 | 0 | 1 |
| Arabic | 1 | 0 | 0 | 1 |
| Caucasian/Asian | 0 | 1 | 0 | 1 |
| Hispanic/Latino | 0 | 2 | 0 | 2 |
| Hispanic | 0 | 1 | 3 | 4 |
| Hispanic And Caucasian | 0 | 0 | 1 | 1 |
| Anglo Indian | 0 | 0 | 1 | 1 |
| Black, White, American Indian | 0 | 0 | 1 | 1 |
| Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures(seizures) | GWP42003-P 25 mg/kg/Day | GWP42003-P 50 mg/kg/Day | Placebo | Total |
|---|---|---|---|---|
| Mean | 77.95 ± 83.390 | 92.95 ± 89.782 | 89.22 ± 101.778 | 86.66 ± 91.841 |
| Number of Total Seizures(seizures) | GWP42003-P 25 mg/kg/Day | GWP42003-P 50 mg/kg/Day | Placebo | Total |
|---|---|---|---|---|
| Mean | 80.87 ± 84.676 | 108.06 ± 115.699 | 118.32 ± 211.868 | 102.44 ± 148.495 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2016 to primary completion in Jan 2019, 33 months.
Results were first posted in Sep 2020, 1 year 8 months after primary completion. A results delay was requested in Jan 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol